← Back to Clinical Trials
Recruiting NCT06115746

NCT06115746 A Randomized Clinical Trial of a Novel Drug Education and Diversion Program (iDECIDE) for Middle and High School Students

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06115746
Status Recruiting
Phase
Sponsor Massachusetts General Hospital
Condition Substance Use
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2023-11-17
Primary Completion 2028-07-31

Trial Parameters

Condition Substance Use
Sponsor Massachusetts General Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age 9 Years
Max Age 22 Years
Start Date 2023-11-17
Completion 2028-07-31
Interventions
iDECIDE

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The primary goal of this study is to test the effectiveness of the iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment) curriculum, a novel drug education and diversion program, in approximately 300 middle and high school students, who have violated their school substance use policies in the past month, as an alternative to punitive school responses for school-based substance use infractions. This randomized controlled trial will test the hypothesis that adolescents randomized to the iDECIDE curriculum will have improved substance use outcomes (i.e., knowledge, attitudes, and behavior) compared to adolescents in a waitlist control group. The outcomes of this study will measure knowledge of drug effects and brain development, perceptions of harm from substance use, willingness to quit or reduce use, and substance use behavior.

Eligibility Criteria

Inclusion Criteria: 1. Currently enrolled in middle or high school; 2. Violated school substance use policy within approximately the past month at the time of screening; 3. Have a parent or legal guardian who is able and willing to provide written informed consent (if under the age of 18); 4. Competent and willing to provide written informed assent (if under the age of 18) or written informed consent (if age 18 or older); 5. Able to commit to 9 study visits over approximately one year; 6. Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the investigator; 7. Has access to a reliable internet connection and a device that can run Zoom; 8. Able to read and write comfortably in one of the languages spoken by study staff. Exclusion Criteria: 1. Ever received substance use treatment in an inpatient or specialty care setting; 2. Ever engaged in intravenous (IV) drug use; 3. Current daily use of alcohol, non-medical benzodiazepines, and/

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology